Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin added to standard BPaL therapy for multidrug-resistant tuberculosis
ISRCTN15045418Phase 2Recruiting
- Sponsor
- Shaheed Zulfiqar Ali Bhutto Medical University
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of metformin in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Shaheed Zulfiqar Ali Bhutto Medical University. Started Nov 2026; status: recruiting.
02
Drugs
metformin
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on ISRCTN15045418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15045418.